H. Hochster

Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors (2003)

Goel, S., Bulgaru, A., Hochster, H., Wadler, S., Zamboni, W., Egorin, M., ...

Background: The aim of this study was to determine the maximum tolerated dose, recommended phase II dose (RPTD) and toxicities of the FOG regimen (infusional 5-fluorouracil, oxaliplatin,...

A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer (2000)

Schilsky, R. L., Bukowski, R., Burris, H., Hochster, H., O'Rourke, M., Wall, J. G., ...

Purpose: To evaluate the safety and efficacy of a five-day regimen of oral 5-fluorouracil (5-FU) plus eniluracil (776C85) in patients with metastatic colorectal cancer (CRC). Patients and methods:...

Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older (1999)

Vogel, C., O'Rourke, M., Winer, E., Hochster, H., Chang, A., Adamkiewicz, B., ...

Background: Older patients with advanced breast cancer are less likely to receive chemotherapy than younger patients. Vinorelbine is an attractive alternative in this setting because of its clinical...